Logos Global Management’s Aligos Therapeutics ALGS Stock Holding History

Logos Global Management’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-40,000	Closed	-$874K	–	52
2023 Q1	$874K	Buy	+40,000	New	+$1.53M	0.13%	40
2022 Q1	–	Sell	-124,511	Closed	-$36.9M	–	48
2021 Q4	$36.9M	Buy	124,511 +46,000	+59%	+$16.8M	3.81%	9
2021 Q3	$30.4M	Buy	78,511 +70,000	+822%	+$27.7M	2.2%	17
2021 Q2	$4.34M	Sell	8,511 -10,551	-55%	-$6.73M	0.36%	45
2021 Q1	$10.8M	Sell	19,062 -5,200	-21%	-$3.46M	1.06%	20
2020 Q4	$16.8M	Buy	+24,262	New	+$11.8M	1.44%	16

Other funds holding ALGS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Logos Global Management's ALGS Position: Q2 2023 in Review

Logos Global Management sold out of Aligos Therapeutics (ALGS) in Q2 2023, closing a stake of 40,000 shares — an estimated $874K sold.

Logos Global Management first reported a position in ALGS in Q4 2020 and held it in 6 quarters. The position peaked at $36.9M in Q4 2021. 41 funds tracked by Wall St. Rank hold ALGS as of Q2 2023.

Logos Global Management reported no remaining Aligos Therapeutics position as of Q2 2023 after selling out during the quarter.
Logos Global Management sold 40,000 Aligos Therapeutics shares in Q2 2023, an estimated $874K.
Logos Global Management first reported a position in Aligos Therapeutics in Q4 2020 and held it in 6 quarters.
Logos Global Management's Aligos Therapeutics position peaked at $36.9M in Q4 2021.
41 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2023.

Based on Logos Global Management's 13F filing for Q2 2023, filed 14 Aug 2023.